A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)
Phase: Phase II clinical trials
Principal Investigator: Dott. Lo Russo Giuseppe
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: Visugromab (CTL-002)
Pathologies: Lung cancer
A phase 2b randomized, placebo-controlled, blinded clinical trial investigating the efficacy and safety of visugromab (CTL-002) in combination with carboplatin, pemetrexed, and pembrolizumab in patients with newly diagnosed metastatic non-squamous non-small cell lung cancer. The study is divided into three parts:
Part A: A non-randomized study to assess the safety of the combination of visugromab with standard treatment (carboplatin, pemetrexed, and pembrolizumab), with the determination of the Recommended Dose for Expansion (RDE).
Part B: A randomized study to compare the efficacy and safety of visugromab in combination with standard treatment (Arm A) versus placebo plus standard treatment (Arm B).
Part C: Continuation of enrollment for further evaluation of the efficacy and safety of the treatment.
The treatment includes an induction phase with carboplatin, pemetrexed, pembrolizumab, and visugromab or placebo, followed by a maintenance therapy with pembrolizumab, pemetrexed, and visugromab or placebo.
Last update: 13/07/2026